文献速递肝病消化道肿瘤与早癌

靶向MMP9在CTNNB1突变肝细胞癌中恢复CD8+ T细胞介导的抗肿瘤免疫并提高抗PD-1疗效

Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8+ T cell-mediated antitumour immunity and improves anti-PD-1 efficacy.
PubMed 文献 · Gut · 2024-05-10

该研究探讨CTNNB1功能获得性突变肝细胞癌免疫逃逸机制,发现MMP9显著上调并抑制CD8+ T细胞浸润与细胞毒性,CTNNB1通过下调SIRT2促进β-catenin/KDM4D复合物形成激活MMP9转录,MMP9阻断可重塑肿瘤免疫微环境并增强抗PD-1疗效。

要点

  • MMP9在CTNNB1功能获得性突变肝细胞癌中显著上调,抑制CD8+ T细胞浸润和细胞毒性。
  • CTNNB1突变下调SIRT2,促进β-catenin/KDM4D复合物形成,激活MMP9转录。
  • MMP9阻断可重塑肿瘤免疫微环境并增强肝细胞癌抗PD-1治疗敏感性。

核心结论

  • CTNNB1功能获得性突变通过激活MMP9分泌诱导抑制性肿瘤免疫微环境,靶向MMP9可重塑免疫微环境并增强CTNNB1功能获得性突变肝细胞癌的抗PD-1疗效。

研究设计与样本

  • 研究采用RNA测序鉴定CTNNB1功能获得性突变下游免疫逃逸关键基因,并使用体外共培养系统、小鼠皮下或原位模型、条件基因敲除小鼠自发成瘤模型及流式细胞术探索MMP9功能,采用单细胞RNA测序和蛋白质组学探讨机制。

主要发现

  • MMP9在CTNNB1功能获得性突变肝细胞癌中显著上调,抑制CD8+ T细胞浸润和细胞毒性,对CTNNB1功能获得性突变驱动抑制性肿瘤免疫微环境和抗PD-1耐药至关重要。
  • 机制上,CTNNB1功能获得性突变下调SIRT2,促进β-catenin/KDM4D复合物形成,激活MMP9转录。
  • 肝细胞癌分泌的MMP9介导CD8+ T细胞表面SSH1脱落,抑制CXCR3介导的G蛋白偶联受体胞内信号。
  • MMP9阻断重塑肿瘤免疫微环境并增强肝细胞癌抗PD-1治疗敏感性。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The gain of function (GOF) CTNNB1 mutations (CTNNB1 GOF ) in hepatocellular carcinoma (HCC) cause significant immune escape and resistance to anti-PD-1. Here, we aimed to investigate the mechanism of CTNNB1 GOF HCC-mediated immune escape and raise a new therapeutic strategy to enhance anti-PD-1 efficacy in HCC. DESIGN: RNA sequencing was performed to identify the key downstream genes of CTNNB1 GOF associated with immune escape. An in vitro coculture system, murine subcutaneous or orthotopic models, spontaneously tumourigenic models in conditional gene-knock-out mice and flow cytometry were used to explore the biological function of matrix metallopeptidase 9 (MMP9) in tumour progression and immune escape. Single-cell RNA sequencing and proteomics were used to gain insight into the underlying mechanisms of MMP9. RESULTS: MMP9 was significantly upregulated in CTNNB1 GOF HCC. MMP9 suppressed infiltration and cytotoxicity of CD8+ T cells, which was critical for CTNNB1 GOF to drive the suppressive tumour immune microenvironment (TIME) and anti-PD-1 resistance. Mechanistically, CTNNB1 GOF downregulated sirtuin 2 (SIRT2), resulting in promotion of β-catenin/lysine demethylase 4D (KDM4D) complex formation that fostered the transcriptional activation of MMP9. The secretion of MMP9 from HCC mediated slingshot protein phosphatase 1 (SSH1) shedding from CD8+ T cells, leading to the inhibition of C-X-C motif chemokine receptor 3 (CXCR3)-mediated intracellular of G protein-coupled receptors signalling. Additionally, MMP9 blockade remodelled the TIME and potentiated the sensitivity of anti-PD-1 therapy in HCC. CONCLUSIONS: CTNNB1 GOF induces a suppressive TIME by activating secretion of MMP9. Targeting MMP9 reshapes TIME and potentiates anti-PD-1 efficacy in CTNNB1 GOF HCC.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Cai N, Cheng K, Ma Y, et al. Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8+ T cell-mediated antitumour immunity and improves anti-PD-1 efficacy. Gut. 2024. PMID: 38123979. doi:10.1136/gutjnl-2023-331342

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。